Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Class(Immunomodulators and Immunosuppressant), By Mode of Administration(Oral and Injection (Intramuscular, Subcutaneous, Intravenous)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031

Global Multiple Sclerosis Drugs Market size was valued at USD 25.40 billion in 2022 and is poised to grow from USD 26.19 billion in 2023 to USD 32.42 billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).

Multiple sclerosis (MS) affects mental, emotional, physical, emotional, visual function and spinal cord. In recent years, the burden of multiple sclerosis seems to be increasing, increasing the demand for chemotherapeutics to adequately address multiple sclerosis. Thus, this increasing burden of multiple sclerosis will provide lucrative growth opportunities for the market during the forecast period.

The growth is attributed to the increasing focus on R&D to develop innovative drugs by major market players. For instance, in December 2020, Adamas Pharmaceuticals Inc. announced results from the phase 3 clinical study on ADS-5102, an investigational amantadine agent for treating MS patients. Product launches, increasing government initiatives to improve the accessibility of treatment & care, and the rising prevalence of multiple sclerosis are expected to result in the global market expansion.

Additionally, important pharmaceutical companies invest in drug development, such as MS treatments. This intranasal anti-CD3 monoclonal antibody, a fully human formulation, is intended for at-home self-administration. It is designed for patients with multiple sclerosis (MS). Thus, recent drug approvals and increased efforts by pharmaceutical companies to develop new therapies are driving market expansion. 

US Multiple Sclerosis Drugs Market is poised to grow at sustainable CAGR for the next forecast year.